Role of Postnatal Corticosteroids in the Treatment or Prevention of Bronchopulmonary Dysplasia

Overview

Journal Sisli Etfal Hastan Tıp Bul

Specialty General Medicine

Date 2023 Oct 30

PMID 37899802

Authors

Ali Bulbul

Tolga Bacak

Hasan Avsar

Affiliations

Soon will be listed here.

Abstract

As the frequency of viable low birth weight preterm babies increases, bronchopulmonary dysplasia (BPD), one of the most important morbidities in these babies, also increases. Using postnatal steroids to reduce the development of BPD has not been fully enlightened. Besides all prevention strategies for reducing the development of BPD, it is known that steroid therapy used in the 1 week of life could induce negative neuromotor development according to current data. It may be recommended to administer low-dose dexamethasone between 8 and 49 days in infants dependent on mechanical ventilators in the postnatal period. It is seen that the use of hydrocortisone in the early period does not cause negative neuromotor development, but it cannot prevent the development of BPD as much as dexamethasone. All intensive care units must have their steroid protocol for BPD and use steroids in cases when the BPD development scale score is >60-65% and should have a goal of trying to keep the cumulative dose at the lowest level.

References

Alvira C, Morty R . Can We Understand the Pathobiology of Bronchopulmonary Dysplasia?. J Pediatr. 2017; 190:27-37. PMC: 5726414. DOI: 10.1016/j.jpeds.2017.08.041. View

NORTHWAY Jr W, ROSAN R, Porter D . Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967; 276(7):357-68. DOI: 10.1056/NEJM196702162760701. View

Doyle L . Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia. Neonatology. 2021; 118(2):244-251. DOI: 10.1159/000515950. View

Bhandari A, Schramm C, Kimble C, Pappagallo M, Hussain N . Effect of a short course of prednisolone in infants with oxygen-dependent bronchopulmonary dysplasia. Pediatrics. 2008; 121(2):e344-9. DOI: 10.1542/peds.2006-3668. View

Yeh T, Lin Y, Lin H, Huang C, Hsieh W, Lin C . Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med. 2004; 350(13):1304-13. DOI: 10.1056/NEJMoa032089. View

Jobe A . The new bronchopulmonary dysplasia. Curr Opin Pediatr. 2010; 23(2):167-72. PMC: 3265791. DOI: 10.1097/MOP.0b013e3283423e6b. View

Doyle L, Davis P, Morley C, McPhee A, Carlin J . Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics. 2006; 117(1):75-83. DOI: 10.1542/peds.2004-2843. View

Stoll B, Hansen N, Bell E, Walsh M, Carlo W, Shankaran S . Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993-2012. JAMA. 2015; 314(10):1039-51. PMC: 4787615. DOI: 10.1001/jama.2015.10244. View

Renolleau C, Toumazi A, Bourmaud A, Benoist J, Chevenne D, Mohamed D . Association between Baseline Cortisol Serum Concentrations and the Effect of Prophylactic Hydrocortisone in Extremely Preterm Infants. J Pediatr. 2020; 234:65-70.e3. DOI: 10.1016/j.jpeds.2020.12.057. View

10.

Kersbergen K, de Vries L, van Kooij B, Isgum I, Rademaker K, van Bel F . Hydrocortisone treatment for bronchopulmonary dysplasia and brain volumes in preterm infants. J Pediatr. 2013; 163(3):666-71.e1. DOI: 10.1016/j.jpeds.2013.04.001. View

11.

Williams E, Dassios T, Mann M, Greenough A . The effect of postnatal corticosteroids on growth parameters in infants with bronchopulmonary dysplasia. J Perinat Med. 2021; 49(9):1141-1144. DOI: 10.1515/jpm-2021-0149. View

12.

Mizikova I, Ruiz-Camp J, Steenbock H, Madurga A, Vadasz I, Herold S . Collagen and elastin cross-linking is altered during aberrant late lung development associated with hyperoxia. Am J Physiol Lung Cell Mol Physiol. 2015; 308(11):L1145-58. DOI: 10.1152/ajplung.00039.2015. View

13.

Harmon H, Jensen E, Tan S, Chaudhary A, Slaughter J, Bell E . Timing of postnatal steroids for bronchopulmonary dysplasia: association with pulmonary and neurodevelopmental outcomes. J Perinatol. 2020; 40(4):616-627. PMC: 7101070. DOI: 10.1038/s41372-020-0594-4. View

14.

Hennelly M, Greenberg R, Aleem S . An Update on the Prevention and Management of Bronchopulmonary Dysplasia. Pediatric Health Med Ther. 2021; 12:405-419. PMC: 8364965. DOI: 10.2147/PHMT.S287693. View

15.

Belcastro R, Lopez L, Li J, Masood A, Tanswell A . Chronic lung injury in the neonatal rat: up-regulation of TGFβ1 and nitration of IGF-R1 by peroxynitrite as likely contributors to impaired alveologenesis. Free Radic Biol Med. 2014; 80:1-11. DOI: 10.1016/j.freeradbiomed.2014.12.011. View

16.

Mandell E, Kratimenos P, Abman S, Steinhorn R . Drugs for the Prevention and Treatment of Bronchopulmonary Dysplasia. Clin Perinatol. 2019; 46(2):291-310. DOI: 10.1016/j.clp.2019.02.011. View

17.

Baud O, Maury L, Lebail F, Ramful D, El Moussawi F, Nicaise C . Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet. 2016; 387(10030):1827-36. DOI: 10.1016/S0140-6736(16)00202-6. View

18.

Savani R . Modulators of inflammation in Bronchopulmonary Dysplasia. Semin Perinatol. 2018; 42(7):459-470. PMC: 6368974. DOI: 10.1053/j.semperi.2018.09.009. View

19.

OConnor K, Hurst C, Llewellyn S, Davies M . Factors associated with successful extubation following the first course of systemic dexamethasone in ventilator-dependent preterm infants with or at risk of developing bronchopulmonary dysplasia. Pediatr Pulmonol. 2022; 57(4):1031-1041. DOI: 10.1002/ppul.25821. View

20.

Liviskie C, Vesoulis Z, Zeller B, Rao R, McPherson C . Respiratory effects of prolonged prednisolone use in infants with evolving and established Bronchopulmonary dysplasia. Early Hum Dev. 2021; 156:105344. DOI: 10.1016/j.earlhumdev.2021.105344. View